In: Angiogenesis, 2015, vol. 18, no. 3, p. 327-345
|
In: Pediatric Nephrology, 2015, vol. 30, no. 1, p. 179-182
|
In: Clinical Oral Investigations, 2015, vol. 19, no. 2, p. 385-399
|
In: Seminars in Immunopathology, 2014, vol. 36, no. 1, p. 73-91
|
In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...
|
In: Cellular and Molecular Life Sciences CMLS, 2003, vol. 60, no. 10, p. 2254-2265
|
In: Journal of Mammary Gland Biology and Neoplasia, 2003, vol. 8, no. 3, p. 269-285
|
In: Journal of Mammary Gland Biology and Neoplasia, 2006, vol. 11, no. 3-4, p. 239-248
|
In: Cellular and Molecular Life Sciences, 2007, vol. 64, no. 21, p. 2746-2762
|
In: Osteoporosis International, 2013, vol. 24, no. 12, p. 2929-2953
|